Finally, stabilization of SREBP-2 or its CTD would provide a molecular basis for the provocative finding that increased serum levels of the SREBP-2 CTD correlate with the clinical severity of COVID-19 by contributing to cytokine storm and pulmonary damage (56). The gene discussed is SREBF2; the disease is COVID-19.